Predicting the Clinical Efficacy of Generic Formulations of Ceftriaxone

References

• Drusano GL, Craig WA. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respi-ratory tract infections. J Chemother 1997; 9 (Suppl 3): 38–44.
   PubMed Web of Science ®Google Scholar
• Dagan R, Klugman KP, Craig WA, Baquero F. Evidence to support the rationale that bacterial eradication in respirato-ry tract infection is an important aim of antimicrobial therapy. J Antimicrob Chemother 2001; 47 (2): 129–140.
   PubMed Web of Science ®Google Scholar
• Leggett JE, Fantin B, Ebert S et al. Comparative antibi-otic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis 1989; 159 (2): 281–292.
   Google Scholar
• Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995; 22 (1-2): 89–96.
   PubMed Web of Science ®Google Scholar
• Andes D, Anon J, Jacobs MR, Craig WA. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections. Clin Lab Med 2004; 24 (2): 477–502.
   PubMed Web of Science ®Google Scholar
• Drusano GL, Goldstein FW. Relevance of the Alexander Project: pharmacodynamic considerations. J Antimicrob Chemother 1996; 38 (Suppl A): 141-154.
   Google Scholar
• Craig WA, Andes D. Pharmacokinetics and pharmacody-namics of antibiotics in otitis media. Pediatr Infect Dis J 1996; 15 (3): 255–259.
   PubMed Web of Science ®Google Scholar
• Brogden RN, Ward A. Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration. Drugs 1988; 35 (6): 604–645.
   PubMed Web of Science ®Google Scholar
• Stratton CW, Anthony LB, Johnston PE. A review of ceftriaxone: a long-acting cephalosporin. Am J Med Sci 1988; 296 (3): 221–222.
   PubMed Web of Science ®Google Scholar
• Barson WJ, Miller MA, Brady MT, Powell DA. Prospective comparative trial of ceftriaxone vs conventional therapy for treatment of bacterial meningitis in children. Pediatr Infect Dis 1985; 4 (4): 362–368.
   PubMedGoogle Scholar
• Lin TY, Chrane DF, Nelson JD, McCracken CH Jr. Seven days of ceftriaxone therapy is as effective as ten days treatment for bacterial meningitis. JAMA 1985; 253 (24): 3559–3563.
   Google Scholar
• Girgis NI, Kilpatrick ME, Farid Z, Mikhail IA, Bishay E. Ceftriaxone versus chloramphenicol in treatment of enteric fever. Drugs Exp Clin Res 1990; 16 (12): 607–609.
   PubMedGoogle Scholar
• Lasserre R, Sangalang RP, Santiago L. Three-day treat-ment of typhoid fever with two different doses of ceftriaxone compared to 14-day therapy with chloramphenicol: a random-ized trial. J Antimicrob Chemother 1991; 28 (5): 765–772.
   PubMed Web of Science ®Google Scholar
• Woodfield JC, Van Rij AM, Pettigrew RA, van der Linden AJ, Solomon C, Bolt D. A comparison of the prophy-lactic efficacy of ceftriaxone and cefotaxime in abdominal surgery. Am J Surg 2003; 185 (1): 45–49.
   PubMed Web of Science ®Google Scholar
• Yuk JH, Nightingale CH, Quintiliani R. Clinical phar-macokinetics of ceftriaxone. Clin Pharmacokinet 1989; 17 (4): 223–235.
   PubMed Web of Science ®Google Scholar
• Patel IH, Chen S, Parsonnet M et al. Pharmacokinetics of ceftriaxone in humans. Antimicrob Agents Chemother 1981; 20 (5): 634–641.
   PubMed Web of Science ®Google Scholar
• Fraschini F, Braga PC, Scarpazza G et al. Human pharmacokinetics and distribution in various tissues of ceftriax-one. Chemotherapy 1986; 32 (3): 192–199.
   Google Scholar
• Scaglione F, Raichi M, Fraschini F. Serum protein bind-ing and extravascular diffusion of methoxyimino cephalosporins. Time courses of free and total concentrations of cefotaxime and ceftriaxone in serum and pleural exudate. J Antimicrob Chemother 1990; 26 (Suppl A): 1-10.
   Google Scholar
• Drusano GL. Role of pharmacokinetics in the outcome of infections. Antimicrob Agents Chemother 1988; 32 (3): 289–297.
   PubMed Web of Science ®Google Scholar
• Dudley MN, Ambrose PG. Monte Carlo PK-PD simula-tion and new cefotaxime (CTX), ceftriaxone (CRO) and cefepime (FEP) susceptibility breakpoints for S. pneumoniae, including strains with reduced susceptibility to penicillin. [Abstract 635]. In Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, Sept 27-30, 2002: p. 7.
   Google Scholar
• NCCLS. Performance standards for antimicrobial sus-ceptibility testing: Twelfth informational supplement (M100-S12). NCCLS (2002), Wayne, PA, USA.
   Google Scholar
• Jacobs MR, Felmingham D, Applebaum PC, Grtineberg RN and the Alexander Project Group. The Alexander Project 1998-2000: susceptibility of pathogens isolated from commu-nity-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52 (2): 229-246.
   PubMed Web of Science ®Google Scholar
• Lambert PA, Conway BR. Pharmaceutical quality of ceftriaxone generic drug products compared with Rocephin®. J Chemother 2003; 15 (4): 357–368.
   PubMed Web of Science ®Google Scholar
• Jones ME, Draghi DC, Thornsberry C, Karlowsky JA, Sahm DF, Wenzel RP. Emerging resistance among bacterial pathogens in the intensive care unit - a European and North American Surveillance study (2000-2002). Ann Clin Microbiol Antimicrob 2004; 3: 14 (http://www.ann-clinmicrob.com/content/3/1/14).
   Google Scholar
• Klugman KP. Bacteriological evidence of antibiotic fail-ure in pneumococcal lower respiratory tract infections. Eur Respir J Suppl 2002; 36: 3s-8s.
   Google Scholar
• Giachetto G, Pirez MC, Nanni L et al. Ampicillin and penicillin concentration in serum and pleural fluid of hospital-ized children with community-acquired pneumonia. Pediatr Infect Dis J 2004; 23 (7): 625–629.
   Google Scholar
• Drusano GL, Goldstein FW. Relevance of the Alexander Project: Pharmacodynamic considerations. J Antimicrob Chemother 1996; 38 (Suppl A): 141-154.
   Google Scholar
• Owens RC Jr, Tessier P, Nightingale CH, Ambrose PG, Quintiliani R, Nicolau DP. Pharmacodynamics of ceftriaxone and cefixime against community-acquired respiratory tract pathogens. Int J Antimicrob Agents 2001; 17 (6): 483–489.
   PubMed Web of Science ®Google Scholar
• Agudelo M, Zuluaga AF, Rodriguez C, Salazar BE, Vesga O. Determination of therapeutic equivalence (TE) for 5 generic products (GP) of penicillin G (PEN) using the neu-tropenic murine thigh infection model (NMTIM). [Abstract A-1877]. In Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, Oct 30-Nov 2, 2004: p. 40.
   Google Scholar
• Rodriguez CA, Zuluaga AF, Salazar BE, Agudelo M, Vesga O. Experimental comparison of 11 generic products (GP) of oxacillin (OXA) with the original compound (OC) in terms of concentration of active principle (CAP), in vitro activ-ity, and in vivo efficacy, using the neutropenic murine thigh infection model (NMTIM). [Abstract A-1305]. In Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, Oct 30-Nov 2, 2004: p. 28.
   Google Scholar
• Salazar BE, Zuluaga AF, Rodriguez CA, Agudelo M, Vesga O. Experimental comparison of 7 generic products (GP) of lincomycin (LIN) with the original compound (OC) in terms of concentration of active principle (CAP), in vitro activity, and in vivo efficacy, using the neutropenic murine thigh infection model (NMTIM). [Abstract A-1879]. In Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, Oct 30-Nov 2, 2004: p. 41.
   Google Scholar
• Zuluaga AF, Salazar BE, Loaiza SA, Agudelo M, Vesga O. Therapeutic equivalence (TE) with the original compound (OC) of 8 generic products (GP) of ampicillin (AMP) deter-mined in the neuropenic murine thigh model (NMTIM). [Abstract E-2033]. In Abstracts of the 44th Interscience Conference on antimicrobial Agents and Chemotherapy, Washington DC, Oct 30-Nov 2, 2004: p. 180.
   Google Scholar
• Zuluaga AF, Salazar BE, Galvis W, Agudelo M, Vesga O. In vivo bactericidal efficacy of 10 generic products (GP) of amikacin (AMK) compared with the original compound (OC) in the neuropenic murine thigh model (NMTIM). [Abstract A-1878]. In Abstracts of the 44th Interscience Conference on antimicrobial Agents and Chemotherapy, Washington DC, Oct 30-Nov 2, 2004: p. 41.
   Google Scholar
• Song JH, Jung SI, Ko KS et al. High prevalence of antimicrobial resistance among clinical Streptococcus pneu-moniae isolates in Asia (an ANSORP study). Antimicrob Agents Chemother 2004; 48 (6): 2101–2107.
   PubMed Web of Science ®Google Scholar
• Jones ME, Karlowsky JA, Blosser-Middleton RB et al. Longitudinal assessment of antipneumococcal susceptibility in the United States. Antimicrob Agents Chemother 2002; 46 (8): 2651–2655.
   PubMed Web of Science ®Google Scholar
• Thomas JK, Forrest A, Bhavnani SM et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients dur-ing therapy. Antimicrob Agents Chemother 1998; 42 (3): 521–527.
   PubMed Web of Science ®Google Scholar
• Odenholt I, Gustafsson I, Lowdin E, Cars O. Suboptimal antibiotic dosage as a risk factor for selection of penicillin-resistant Streptococcus pneumoniae: in vitro kinetic model. Antimicrob Agents Chemother 2003; 47 (2): 518-523.
   PubMed Web of Science ®Google Scholar